Dermovate 0.5 mg/ ml Norge - norsk - Statens legemiddelverk

dermovate 0.5 mg/ ml

2care4 aps - klobetasolpropionat - oppløsning - 0.5 mg/ ml

Dermovat 0.05 % Norge - norsk - Statens legemiddelverk

dermovat 0.05 %

2care4 aps - klobetasolpropionat - salve - 0.05 %

Nasonex 50 mikrog/ dose Norge - norsk - Statens legemiddelverk

nasonex 50 mikrog/ dose

farmagon - mometasonfuroat - nesespray, suspensjon - 50 mikrog/ dose

Nasonex 50 mikrog/ dose Norge - norsk - Statens legemiddelverk

nasonex 50 mikrog/ dose

farmagon - mometasonfuroat - nesespray, suspensjon - 50 mikrog/ dose

Elocom 0.1 % Norge - norsk - Statens legemiddelverk

elocom 0.1 %

orifarm as - mometasonfuroat - liniment, oppløsning - 0.1 %

Toradol 30 mg/ ml Norge - norsk - Statens legemiddelverk

toradol 30 mg/ ml

atnahs pharma netherlands b.v. - ketorolaktrometamol - injeksjonsvæske, oppløsning - 30 mg/ ml

Toradol 30 mg/ ml Norge - norsk - Statens legemiddelverk

toradol 30 mg/ ml

2care4 aps - ketorolaktrometamol - injeksjonsvæske, oppløsning - 30 mg/ ml

Enerzair Breezhaler Den europeiske union - norsk - EMA (European Medicines Agency)

enerzair breezhaler

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - legemidler for obstruktive sykdommer i luftveiene, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Bemrist Breezhaler Den europeiske union - norsk - EMA (European Medicines Agency)

bemrist breezhaler

novartis europharm limited  - indacaterol, mometasone furoate - astma - legemidler for obstruktive sykdommer i luftveiene, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Atectura Breezhaler Den europeiske union - norsk - EMA (European Medicines Agency)

atectura breezhaler

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - legemidler for obstruktive sykdommer i luftveiene, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.